Combination therapy for Sneddon syndrome to reduce the incidence of cerebrovascular complications
JDDG: Journal der Deutschen Dermatologischen Gesellschaft · 2024-07 · 22 (7) · 947-954
DOI: 10.1111/ddg.15422 ↗Kurz gefasst
Fachartikel in der Zeitschrift JDDG: Journal der Deutschen Dermatologischen Gesellschaft, online erschienen am 21.06.2024. Verfasst von Albert Narwutsch und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Venereology, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany. Hauptthemen laut MEDLINE: Sneddon Syndrome, Drug Therapy, Combination, Alprostadil. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Sneddon syndrome is an occlusive vasculopathy that presents clinically with generalized livedo racemosa on the skin and transient ischemic attacks, strokes, and cognitive or motor deficits in the central nervous system. Antiplatelet or anticoagulant therapy is recommended. Due to the limited therapeutic efficacy and the resulting serious complications, we propose combination therapy with additional infusion cycles of alprostadil and captopril and report initial long‐term results. Patients and methods We performed a systematic retrospective analysis of all patients with primary Sneddon syndrome who received combination therapy in our clinic between 1995 and 2020. Therapeutic outcomes were evaluated using descriptive statistics compared to historical controls receiving monotherapy. We also analyzed the event rate of complications when combination therapy was discontinued.
Results
During the 99.7 patient‐years of follow‐up, there were no transient ischemic attacks and the stroke rate dropped to 0.02 per patient‐year. In comparison, the rates of transient ischemic attacks and strokes in the historical controls ranged from 0.08 to 0.035 per patient‐year. After discontinuation of alprostadil therapy, eight events occurred in three patients.
Conclusions
Combination therapy reduces the long‐term incidence of ischemic events in patients with primary Sneddon syndrome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology and Venereology, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.
- Department of Neurology, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.
- Saxon Hospital Altscherbitz, Hospital for Psychiatry and Neurology, Schkeuditz, Germany.
ORCID-Profile: Johannes Wohlrab, Cord Sunderkötter
Zitieren
APA
Narwutsch, A., Wohlrab, J., Sperfeld, A. D., & Sunderkötter, C. (2024). Combination therapy for Sneddon syndrome to reduce the incidence of cerebrovascular complications. JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 22(7), 947-954. https://doi.org/10.1111/ddg.15422
Vancouver
Narwutsch A, Wohlrab J, Sperfeld AD, Sunderkötter C. Combination therapy for Sneddon syndrome to reduce the incidence of cerebrovascular complications. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2024;22(7):947-954. doi:10.1111/ddg.15422
BibTeX
@article{Narwutsch2024,
author = {Narwutsch, Albert and Wohlrab, Johannes and Sperfeld, Anne-D and Sunderkötter, Cord},
title = {Combination therapy for Sneddon syndrome to reduce the incidence of cerebrovascular complications},
journal = {JDDG: Journal der Deutschen Dermatologischen Gesellschaft},
year = {2024},
volume = {22},
number = {7},
pages = {947--954},
doi = {10.1111/ddg.15422}
}
EUVIMED